References
- Kastrati A, Schomig A, Elezi S et al Predictive factors of restenosis after coronary stent placement. J. Am. Coll. CardioL 30, 1428–1436 (1997).
- Hausleiter J, Kastrati A, Mehilli J et al Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. Arn. Coll. CardioL 40, 882–889 (2002).
- Hoffmann R, Mintz GS, Dussaillant GR et al. Patterns and mechanisms on in-stent restenosis: a serial intravascular ultrasound study. Chrulation 94, 1247–1254 (1996).
- Waksman R, Ajani AE, White RL et al. Prolong antiplatelet therapy to prevent late thrombosis after intracoronary 7-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent restenosis Trial PLUS 6 months of clopidogrel (WRIST PLUS). Circulation 103, 2332–2335 (2001).
- Waksman R, Ajani AE, Pinnow E et al 12 versus 6 months of clopidogrel to reduce major cardiac events in patients undergoing 7-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 106, 776–778 (2003).
- Froeschl M, Olsen S, Ma X, O'Brien ER. Current understanding of in-stent restenosis and potential benefit of drug eluting stents. CUIT: Drug Targets Cardiovasc. Haematol. Disord. 4, 103–117 (2004).
- Cheng-Lai A, Prishman WH. Sirolimus- eluting coronary stents: novel devices for the management of coronary artery disease. Am. J Ther. 11, 218–228 (2004).
- Eikelboom JW, Lonn E, Genest J Jr et al. Homocyst(e)ine and cardiovascular diseases: a critical review of the epidemiologic evidence. Ann. Intern. Med. 131, 363–375 (1999).
- Chai AU, Abrams J. Homocysteine: a new cardiac risk factor? Clin. Cardial. 24, 80–84 (2001).
- Kumbasar SD, Dincer I, Ertas F et al. Hyperhomocysteinemia and restenosis. Cardiovasc. Risk 8, 9–13 (2001).
- Kosokabe T, Okumura K, Sone T et al. Relation of a common methylenetetrahydrofolate reductase mutation and plasma homocysteine with intimal hyperplasia after coronary stenting. Circulation 103, 2048–2054 (2001).
- Koch W, Ndrepepa G, Mehilli J et al.Homocysteine status and polymorphisms of methylenetetrahydrofolate reductase are not associated with restenosis after stenting in coronary arteries. Arterioscler. Thromb. Vasc. Biol. 23, 2229–2234 (2003).
- Genser D, Prachar H, Hauer R et alRelation of homocysteine, vitamin B12 and folate to coronary in-stent restenosis. Am. J Cardial. 89, 495–499 (2002)
- Zairis MN, Ambrose JA, Manousakis ST et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting. J Am. Coll. Cardial. 40, 1375–1382 (2002).
- Kojoglanian SA, Jorgensen MB, Wolde-Tsadik G et al. Restenosis in Intervened Coronaries with Hyperhomocysteinemia (RICH). Am. Heart J. 146, 1077–1081 (2003).
- Ortolani P, Marzocchi A, Marrozzini C et al. Clinical relevance of homocysteine levels in patients receiving coronary stenting for unstable angina. ItaL Heart J. 5, 189–196 (2004).
- Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl. J Med. 345, 1593–1600 (2001).
- Schnyder G, Roffi M, Rammer Y et al. Effect of homocysteine-lowering therapy on restenosis after percutaneous coronary intervention for narrowing in small coronary arteries. Am. Cardiol. 91, 1265–1269 (2003).
- Lange H, Suryapranata H, De Luca G et al. Palate therapy and in-stent restenosis after coronary stenting. N Engl. J. Med. 350, 2673–2681 (2004).